• The new Atrys SIMM digital PET-CT scanner in Barcelona features an extended PET detection field of 30 centimetres, twice that of conventional digital PET scanners

• The technology enables the detection of smaller lesions with higher image quality, and reduces scan time and radiation dose by up to 50%

• The system has a significant clinical impact in oncology, as well as in neurology, cardiology and the study of infectious and inflammatory diseases

Atrys Health, a medical company specialising in healthcare services in the fields of telediagnostics, oncology, pathological anatomy and nuclear medicine, has installed United Imaging Healthcare’s uMI PanVivo digital PET-CT system at its Atrys SIMM Irla centre in Barcelona; this state-of-the-art equipment is currently the most advanced of its kind in Spain.

This system stands out for its extended PET detection field of 30 centimetres—almost double that of conventional equipment—and for the incorporation of high-precision crystals, which enable very high-resolution imaging. These capabilities significantly improve diagnostic sensitivity, facilitating the detection of smaller lesions and the identification of findings that might go unnoticed with standard technologies.

Furthermore, the equipment enables scans to be performed up to 50% faster, whilst also reducing the radiation dose by up to 50%, thereby improving the patient experience. This advantage is particularly significant in cases requiring periodic check-ups or follow-up scans. The installation and commissioning of the system was carried out with the involvement of APR Salud, United Imaging Healthcare’s partner in Spain.

“Having Spain’s most advanced wide-field digital PET scanner enables us to provide more accurate diagnoses, with lower radiation exposure and in less time. It represents a qualitative leap that strengthens our ability to detect disease and optimise clinical decision-making in complex conditions,” says Isabel Roca, Head of Nuclear Medicine at Atrys.

For his part, Íñigo Valcaneras, Country Manager at Atrys Spain, highlights that “this technology also represents a step forward from an operational perspective, as it allows us to increase our patient care capacity and reduce waiting times, thereby supporting the growth of our business”.

Diagnostics with wide-ranging clinical impact

The uMI PanVivo PET-CT is a highly versatile diagnostic device, the clinical application of which depends on the radiopharmaceutical used. In oncology, it is used for initial diagnosis, staging, monitoring, detecting recurrence and evaluating treatment in various types of cancer, particularly lung, prostate and breast cancer.

Beyond the field of oncology, the system extends its applications to neurology—including neurodegenerative diseases such as Parkinson’s or Alzheimer’s—as well as to cardiology and the analysis of infectious and inflammatory processes. It will also enable the development of advanced clinical trials in both oncology and neurology.

The device has already begun clinical use and performed its first scan on 4 May. Its integration into the Atrys network in Catalonia strengthens the capacity to care for private patients, those from partner organisations and hospitals.

Studies conducted using this technology will be integrated into the multidisciplinary committees in which the company participates, contributing to more precise and personalised treatment planning for each patient.

With this addition, Atrys consolidates its position as a leader in highly specialised nuclear medicine, expanding the available diagnostic capacity and moving towards more precise, efficient and patient-centred care.